海尔生物：2025年实现归母净利润2.5亿元，同比下滑31.6%

Group 1 - The company reported a revenue of 2.33 billion yuan for 2025, representing a year-on-year growth of 2.0%, continuing the acceleration from 2024 [1] - In Q4 2025, the revenue growth rate was 13.1%, indicating a sustained internal growth momentum [1] - The overseas revenue reached 840 million yuan, a year-on-year increase of 17.9%, accounting for 36% of the main revenue, up 5 percentage points from 2024 [1] Group 2 - Domestic revenue was 1.47 billion yuan, down 5.5% year-on-year, but showed a recovery trend with a 14.5% growth in Q4 [1] - The company is focusing on AI and automation technology, with AI-related revenue making up 15% of total revenue, an increase of 2.5 percentage points from 2024 [1] - The net profit attributable to the parent company was 250 million yuan, a decline of 31.6% year-on-year [1] Group 3 - The gross margin for the reporting period was 46.8%, affected by the ramp-up of new factory capacity, but improved by approximately 0.7 percentage points in Q4 [2] - The company is investing in long-term strategies to address external challenges, focusing on globalization and innovation [2] - New localized operational systems were established in six locations, including Japan and Brazil, to enhance market promotion in Asia-Pacific and Europe [2]